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University, Maastricht, The NetherlandsA B S T R A C TObjectives: Many national colorectal cancer screening campaigns
have a similar structure. First, individuals are invited to take a
noninvasive screening test, and, second, in the case of a positive
screening test result, they are advised to undergo a more invasive
follow-up test. The objective of this study was to investigate how
much individuals’ participation decision in noninvasive screening
is affected by the presence or absence of detailed information about
invasive follow-up testing and how this effect varies over
screening tests. Methods: We used a labeled discrete choice experi-
ment of three noninvasive colorectal cancer screening types with
two versions that did or did not present respondents with detailed
information about the possible invasive follow-up test (i.e., colono-
scopy) and its procedure. We used data from 631 Dutch respondents
aged 55 to 75 years. Each respondent received only one of the two
versions (N ¼ 310 for the invasive follow-up test information
speciﬁcation version, and N ¼ 321 for the no-information speciﬁ-
cation version). Results: Mixed logit model results show thatee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.04.007
ing@uvt.nl.
ondence to: Tim M. Benning, CentERdata, Roomdetailed information about the invasive follow-up test negatively
affects screening participation decisions. This effect can be explained
mainly by a decrease in choice shares for the most preferred screening
test (a combined stool and blood sample test). Choice share simulations
based on the discrete choice experiment indicated that presenting
invasive follow-up test information decreases screening participation
by 4.79%. Conclusions: Detailed information about the invasive follow-
up test has a negative effect on individuals’ screening participation
decisions in noninvasive colorectal cancer screening campaigns. This
result poses new challenges for policymakers who aim not only to
increase uptake but also to provide full disclosure to potential screen-
ing participants.
Keywords: colorectal cancer, conjoint analysis, public health,
preferences, The Netherlands.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Many national colorectal cancer (CRC) screening campaigns have
a similar structure in that, ﬁrst, individuals are invited to take a
noninvasive screening test (e.g., fecal occult blood test [FOBT]),
and, second, in the case of a positive screening test result, they
are advised to undergo a more invasive follow-up test (e.g.,
colonoscopy). Previously, in the literature on participants’ CRC
screening preferences, little emphasis has been placed on this
multilayered character of national campaign-based CRC screen-
ing. Several studies investigated the preferences of the general
public for noninvasive screening tests only [1–5]. For example,
Nayaradou et al. [4] studied the French public’s preferences for
noninvasive screening tests while Benning et al. [1] recentlystudied preferences for innovative noninvasive screening tests
in The Netherlands. Other studies simultaneously elicited pref-
erences for noninvasive screening tests and invasive tests by
allowing individuals to also choose direct invasive “follow-up”
testing without participating in noninvasive screening ﬁrst [6–11].
Marshall et al. [9], for example, found that the greatest impact on
uptake might be achieved if all endorsed CRC screening tests
were available, including FOBT, double contrast barium enema,
ﬂexible sigmoidoscopy, colonoscopy, and computed tomography
colonography, instead of limiting the choice to FOBT.
Likewise, in several recent studies in which CRC screening
preferences of the Dutch population were investigated [6,8,11],
individuals also had a direct choice between noninvasive (i.e.,
FOBT) and invasive tests (i.e., ﬂexible sigmoidoscopy orociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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improvements in the awareness on CRC mortality reduction
and the use of shorter screening intervals may increase screening
participation in such a setting. Furthermore, Hol et al. [8] found
that a ﬂexible sigmoidoscopy and colonoscopy were preferred
over FOBT by both naive as well as previously screened subjects
and that risk reduction (RR) dominated screening preferences.
Moreover, by comparing the results of a labeled and unlabeled
discrete choice experiment (DCE), De Bekker-Grob et al. [6]
found that the use of a labeled design increased the validity of
the results but that the use of labels also reduced the attention
given to the attributes. For a more exhaustive overview of
previous DCE-based studies about CRC screening, we refer to
Table 1.
A possible limitation of the aforementioned studies is that, in
Europe, large-scale CRC screening campaigns more commonly use
a multilayered approach in which noninvasive screening tests are
followed by a more invasive follow-up test (colonoscopy) in case of
a positive screening test result [12]. This screening procedure is
also used in the Dutch screening campaign that recently started in
2014. Therefore, in this research, we extend previous analyses by
investigating an intermediate approach that varies how much
information about possible invasive follow-up testing is provided
to participants in a noninvasive screening context without offering
the option to directly choose such an invasive test. Speciﬁcally, we
were interested in knowing how much individuals’ participation
decisions in noninvasive screening are affected by the presence or
absence of detailed information about invasive follow-up testing
and how this effect varies over screening tests. Despite the fact
that most of the earlier studies on noninvasive screening implic-
itly addressed the issue of follow-up testing by including attributes
such as the number of false-positives or unnecessary colonos-
copies [1–5,9,10,13,14], none of these focused on how providing
detailed information about a future invasive follow-up test (e.g.,
colonoscopy) affects individuals’ participation decision in
campaign-based noninvasive CRC screening—in this study, two
separate versions of a discrete choice survey were used to
explicitly address this issue. One notable exception is Marshall
et al. [10] who included an attribute about the possible need for
follow-up testing in their DCE and investigated how physician
assessments of patients’ preferences differed from actual prefer-
ences. They did not, however, provide speciﬁc information about
the follow-up test and there was also no contrast made between
presenting detailed follow-up test information to respondents or
not. Note, furthermore, that the attribute “need for follow-up
testing” was found to be nonsigniﬁcant in their study.
We propose that in individuals’ willingness to participate in
screening, the possible need to undergo a more invasive follow-
up test is likely to also be of inﬂuence. The reason is that the
consideration of future consequences has been found to play a
role in forming intentions regarding screening participation [15].
In particular, we predict that providing extensive information
about the follow-up test affects individuals’ screening participa-
tion decisions. It is likely that individuals will more carefully
consider this type of information for their participation decision
when it is explained in detail and that this may lower the
probability of participation, in particular when the follow-up test
is invasive. More speciﬁcally, it may lower the probability of
participating in more sensitive and less speciﬁc tests (e.g., a
combi test) because this type of test is more likely to lead to
(unnecessary) follow-up testing.
In short, this article speciﬁcally addresses the issue how
presenting information about the possible future invasive follow-
up test affects individuals’ decision to participate in noninvasive
screening by means of a DCE in the ﬁeld of CRC screening.
Screening for this disease provides a suitable context for our
research because it matches the typical multilayer character ofscreening quite well (i.e., a noninvasive screening test followed by
an invasive follow-up test in case of a positive screening test
result). Furthermore, the yearly prevalence and mortality rates for
CRC are high enough that several countries provide regular screen-
ing invitations to the population.
Based on the fact that individuals have rather limited knowl-
edge about CRC screening and the embarrassing and uncomfort-
able nature of follow-up testing [16–18], we hypothesize that
when individuals are extensively informed about the invasive
follow-up test (i.e., colonoscopy), screening uptake in our DCE
context may be lower than in the situation in which this is not
the case. Moreover, we predict that there is a negative moderat-
ing effect of follow-up test information on the preference for the
combi test relative to the blood and stool tests due to the combi
test’s higher likelihood of providing false-positive test results. We
particularly focus on the effect that the presentation of detailed
follow-up test information has on expected screening uptake
because of the relatively low expected CRC screening participa-
tion rates in The Netherlands [19,20].Methods
DCE
DCEs measure individuals’ preferences for goods and services [21–
23]. The technique is increasingly used for health care purposes,
such as the evaluation of health care interventions [24]. It
describes interventions in terms of speciﬁc attributes (i.e., charac-
teristics), which each take on different (attribute) levels. The levels
of the attributes are varied on the basis of an experimental design
that deﬁnes a series of tasks that describe two or more interven-
tions fromwhich individuals are asked to choose the one that they
prefer the most [21–23]. A DCE has several advantages over less
complicated methods such as alternative survey designs because
it enables one to investigate many types of questions [25] related
to, for example, the relative importance of and trade-offs between
attributes or the prediction of market shares (i.e., the percentage of
people expected to choose a particular screening test relative to
other available tests).
Selection of attributes and attribute levels
In the two follow-up test speciﬁcation versions of the survey, the
attribute follow-up test was either present or absent, and it
presented information about the type of follow-up test that is
conducted in the case of a positive screening test result (see below
for further speciﬁcation). This attribute was included to be able to
address our main research question whether presenting detailed
follow-up test information affects individuals’ screening partic-
ipation decision. We based the attributes of the three screening
tests on a review of studies that have previously measured
preferences for CRC screening tests by means of discrete choice
and conjoint analysis methods. The attributes that we selected
are sensitivity, the number of unnecessary colonoscopies (i.e.,
false-positive test results), the RR of CRC death, the scientiﬁc level
of evidence, and the follow-up test used after a positive screening
test result. The ﬁrst three attributes are used most frequently in
the reviewed studies [2–11,13,14], and their importance was also
conﬁrmed by experts in the ﬁeld (n ¼ 3). Strength of the evidence
is also relevant in health care decisions [5,26,27], and therefore the
fourth attribute was included to indicate this aspect of the test.
Individuals may consider the scientiﬁc evidence of CRC screening
tests in their screening participation decision [28].
The attributes’ levels were selected using the previously
described review of studies and were also validated with opinions
of the three earlier mentioned experts in the ﬁeld of CRC screen-
ing. Furthermore, we studied CRC-related mortality-risk data from
Table 1 – Overview of DCE-based studies about colorectal cancer screening.
Study Country Admini-
stration
Sample Screening test Label Survey
type
Non-
invasive
Invasive
Gyrd-Hansen and
Søgaard (2001) [2]
Denmark Interview 509 participants aged 50 years from a random sample of the
Danish population
FOBT No Ranking
task
Salkeld et al. (2003)
[5]
Australia Interview 301 participants living in central Sydney, aged 50-70 years at
average risk, eligible for screening
FOBT No Choice
task
Ryan and San Miguel
(2003) [13]
UK Internet 293 students from the University of Aberdeen Not speciﬁed Not
speciﬁed
No Choice
task
Berchi et al. (2006)
[14]
France Mail 700 randomly selected GP’s from two types of French departments
(organized vs. never organized CRC screening)
FOBT No Choice
task
Marshall et al. (2007)
[9]
Canada Mail 1170 randomly selected patients aged 40-60 years from the Stoney
Creek and Mountain Primary Care Network in Hamilton Ontario
FOBT, DNA DCBE, FS,
COL, VC
No Choice
task*
Hawley et al. (2008)
[7]
USA Waiting
rooms
212 patients aged 50-80 years from a purposeful sample for race
and ethnicity with no personality or family history of CRC from
an urban practice-based research network in Michigan
FOBT, FIT DCBE, FS,
COL, VC
No Rating
task
Howard and Salkeld
(2009) [3]
Australia Mail 1920 participants who had purchased a FOBT from the Bowel scan
Program in Australia in the last 12 months (2004-2005)
FOBT No Choice
task
Marshall et al. (2009)
[10]
Canada USA Internet
mail
501 Canadian and 1087 US participants aged 45-70 years from a
Harris Interactive general population panel; 100 Canadian and
100 US general practice physicians from the medical directory
FOBT, DNA DCBE, FS,
COL, VC
No Choice
task*
Hol et al. (2010) [8] Netherlands Mail 1498 screening naïve participants aged 50-74 years randomly
selected from municipal registries of Rotterdam region
(Netherlands), and 769 screened subjects of a CRC screening trial
(random sample from the same target population).
FOBT FS, COL Yes Choice
task*
De Bekker-Grob et al.
(2010) [6]
Netherlands Mail Subjects from a recent regional call-recall CRC screening program
(unlabeled n ¼ 212; labeled n ¼ 769) and randomly selected
screening naive subjects of the same region (Groot-Rijnmond)
(unlabeled n ¼ 500; labeled n ¼ 1498)
FOBT FS, COL Both Choice
task*
Van Dam et al. (2010)
[11]
Netherlands Mail 500 screening naïve participants aged 50-74 years randomly
selected from the population registry from region Rijnmond
(Netherlands), and 210 participants of a randomized screening
trial for CRC from the same target population.
FOBT FS, COL No Choice
task*
Nayaradou et al.
(2010) [4]
France Mail Representative sample of 2000 inhabitants aged 50-74 from
Northwestern France (10 French departments, 4 had already
organized CRC screening campaigns) randomly selected from
electoral lists
FOBT (Blood
or stool
sample)
No Choice
task
Benning et al. (2014)
[1]
Netherlands Internet A representative sample (age: between 55-75 years, gender: almost
equal % of males and females) of 1575 individuals from the
Dutch screening population
FOBT (Blood
or stool
sample)
Yes Choice
task
FOBT, Fecal occult blood test; DCBE, Double contrast barium enema; FS, Flexible sigmoidoscopy; Col, Colonoscopy; VC, Virtual colonoscopy; DNA, Fecal DNA testing; FIT, Fecal
immunochemical test.
* Non-invasive and invasive screening tests were offered simultaneously in the choice tasks.
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attribute levels used by comparing information from the literature
with the available data on CRC-related mortality risk [29] where
probabilities of CRC-related mortality are calculated using pre-
speciﬁed levels of sensitivity and speciﬁcity. Note that attribute
levels for the combi test are different from those of the stool and
blood tests because the chance of being more sensitive and less
speciﬁc is higher for this test. For a complete overview of the
attributes and attribute levels used, we refer to Table 2.
In each task of the DCE, we presented three different screening
tests (a stool test, a blood test, and a combi test) to respondents as
well as a no-participation option for individuals who prefer not to
be screened, as in Benning et al. [1]. The stool test is based on taking
a stool sample by means of a test-kit at home and sending this test-
kit to the laboratory. The blood test is based on taking a blood
sample at the hospital. Finally, the combi test is a test based on a
combination of the blood and stool tests. This means taking both a
stool sample at home, by means of a test-kit, and a blood sample at
the hospital. The reasons for using these tests are recent develop-
ments in research on new molecular marker-based screening tests
that suggest that the tests may become available in practice. Bosch
et al. [30], for example, made a distinction between molecular
markers for the detection of CRC in both the blood and the stool.
We used the distinction between stool and blood tests to assess the
role of individuals’ aversion to handling stools [4], whereas the
combi test is added to investigate what actions individuals are
willing to participate in for the sake of a “better” test. Note that our
explicit choice for the use of a labeled design is based on individ-
uals’ familiarity with the drawing of blood at the hospital and the
collection of a stool sample at home and our particular interest in
simulating choice shares and expected screening uptake in a
situation that closely reﬂects real-life screening practices [6] in
which detailed follow-up test information is provided or not.Experimental design
We created a labeled and blocked D-efﬁcient design in Ngene
(ChoiceMetrics 2011) by using zero priors and restrictions [31,32]
for speciﬁc attribute-level combinations (i.e., combinations forTable 2 – Attributes, attribute descriptions, and attribute
Attributes* Attribute description
Follow-up test† Detailed information
decide whether th
Chance that the screening test correctly
identiﬁes that there is a polyp or CRC
(sensitivity)
If there is a polyp or
for … out of 100 p
Chance of an unnecessary follow-up test
(false-positive test result)
The screening test in
and thus leads to
people without a p
Risk reduction of CRC deathǁ By taking part in scre
decreases by … %
Scientiﬁc level of evidence The screening test ch
correctly identiﬁes
“Chance of an unn
CRC death” are ba
CRC, colorectal cancer.
* The text in the table is translated from Dutch.
† The follow-up test attribute was included only in the invasive-follow-u
‡ Levels for stool and blood tests.
§ Levels for the combi test.
ǁ Risk reduction levels are based on participation in a screening campai
follow-up test).the attribute levels of sensitivity and RR). Three tests (and an opt-
out option) were presented to respondents in each choice task,
and the design allowed estimating all two-way interactions
between the attributes. Furthermore, the constant was taken
into account when minimizing the design’s D-error. Three blocks
were used, each consisting of 12 choice tasks, to make the survey
not too demanding for the respondents [33]. We implemented
restrictions such that (1) the lowest sensitivity level was pre-
sented only in combination with one of the two lowest levels of
mortality RR and (2) the highest sensitivity level was presented
only in combination with the two highest mortality RR levels.
These restrictions come at the cost of level balance, but they
increase the realism of the choice tasks.Survey and Sample
We used six different Web-based surveys that were piloted by
colleagues and the survey sample provider. Before launching
with the full sample, we rephrased some parts of the text in the
survey to improve its comprehensibility. The surveys (see
Appendix A in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.04.007) are based on two experimental
invasive follow-up test speciﬁcation conditions (i.e., invasive
follow-up test information and no-information speciﬁcation) that
both consist of the same blocked experimental design (see the
previous section). Respondents were randomly assigned to one of
these two conditions. The invasive follow-up test information
speciﬁcation version reports that a colonoscopy will be recom-
mended in case of a positive screening test result and presents an
additional follow-up test attribute in the choice task with colono-
scopy as a ﬁxed attribute level and detailed colonoscopy infor-
mation (see Table 3). The no-information speciﬁcation version
does not inform the respondents about the type of follow-up test,
and it does not present an additional follow-up test attribute and
thus offers no follow-up test (i.e., colonoscopy) information.
Based on these two follow-up test speciﬁcation versions that
both consist of three blocks, six Web-based surveys were created.
All respondents were told that the Dutch government had
decided to start a national screening campaign for the detectionlevels.
Attribute levels
about the follow-up test (when necessary) to
ere really is a polyp or CRC is
Present
(colonoscopy)
Absent
CRC, the screening test correctly identiﬁes this
eople with a polyp or CRC
50, 70, 90‡
55, 75, 95§
2, 4, 6‡
3, 5, 7§
correctly identiﬁes that there is a polyp or CRC
an unnecessary follow-up test for ... out of 100
olyp or CRC
ening, the chance that you will die from CRC
(from … % to … %)
30, 40, 50‡
35, 45, 55§
aracteristics “Chance that the screening test
that there is a polyp or colorectal cancer,”
ecessary follow-up test,” and “Risk reduction of
sed on
Limited
evidence,
strong
evidence
p test speciﬁcation version.
gn (i.e., risk reduction resulting from a screening test plus possible
Table 3 – Colonoscopy information presented in the
invasive follow-up test speciﬁcation version*.
Procedure Description of procedure
Preparation You have to drink 4 L of a special cleansing
solution the day before the procedure. You
have to fast for 12 h before the procedure.
You cannot work the afternoon before and
the day of the procedure.
The
colonoscopy
You will be given conscious sedation (short
narcosis). Therefore, you may fall into a
light sleep. The entire large bowel (100–120
cm) is examined by using a ﬂexible tube
with a small camera on the tip. This tube is
inserted through the anus. During the
procedure, the large bowel will be ﬁlled with
air to carefully examine the bowel. Because
of the air and tube in your bowel, you may
feel abdominal pressure and cramps.
Precursors of colon carcinoma (polyps) are
removed during the procedure (this is
painless).
After the
colonoscopy
You may eat and drink again and go home
after 1 h. You cannot drive a car or ride a
motorcycle or bicycle.
Perceived
burden
High.
Results Directly after the procedure. When tissue has
been removed, you will receive the
pathology results by mail within 2 wk.
Place of test Hospital.
Total duration 1 h 45 min.
Complications In 1 in 1000 individuals: severe blood loss or a
perforation or a tear through the bowel wall.
* The information in the table is adapted from Hol et al. [8] and
approved by experts in the ﬁeld (n ¼ 3).
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 7 8 – 5 8 7582of CRC in the next year. This was followed by information about
the need of CRC screening, the possible screening tests that can
be used to detect polyps or CRC, and the attributes and attribute
levels used in the choice tasks. Furthermore, they were told about
the fact that a (noninvasive) screening test only indicates
whether an additional follow-up test is necessary and that a
noninvasive screening test does not give a deﬁnite result.
Depending on the survey version, the respondents were either
informed or not informed about the invasive follow-up test (i.e.,
colonoscopy) and its procedure. Then, 13 choice tasks were
presented to the respondents in which they were asked to choose
one of the three available screening tests or the option not to
participate in screening. The ﬁrst start-up question was not used
in the analysis. After the completion of this question, the other 12
choice tasks (see Table 4 for an example) followed. All choice
tasks were compulsory, and the respondents could continue to
the following task only when they provided an answer. Finally,
respondents were asked some demographic questions and were
thanked for their participation in the survey.
Data were collected through an online platform of a Dutch
survey sampling solutions provider. On this platform, 1277
individuals from the general Dutch population in the age cat-
egory 55 to 75 years started our online survey in the period mid-
May to the end of May 2012. Assignment to one of the six survey
versions took place randomly. After completion of the survey, the
respondents were offered the option that a limited amount of
money would be donated on their behalf to a charity for free.Econometric Model
Now we present the utility functions of the estimated model.
Note that the utility function speciﬁcation (e.g., for the stool test
[Ustool]) consists of a systematic component (Vstool) and an error
component (εstool) and that the utility for choosing not to be
screened (Unotest) is used as a reference.
Ustool ¼ Vstool þ εstool
β0 þ β1  Sensitivity þ β2  Unnecessary Follow-Up Test þ β3 
RR þ β4  Level of Evidence þ β5  Invasive Follow-Up Test
Information Speciﬁcation Stool + εstool
Ublood ¼ Vblood þ εblood
β6 þ β1  Sensitivity þ β2  Unnecessary Follow-Up Test þ β3 
RR þ β4  Level of Evidence þ β7  Invasive Follow-Up Test
Information Speciﬁcation Blood + εblood
Ucombi ¼ Vcombi þ εcombi
β8 þ β9  Sensitivity þ β10  Unnecessary Follow-Up Test
þ β11  RR þ β12  Level of Evidence þ β13  Invasive Follow-
Up Test Information Speciﬁcation Combi + εcombi
Unotest ¼ 0
To test whether providing extensive follow-up test informa-
tion affects individuals’ screening participation decision, we
included an effects-coded variable that indicates whether exten-
sive follow-up test information is provided to individuals or not
(follow-up test information provided ¼ 1, follow-up test informa-
tion not provided ¼ 1). We estimate alternative speciﬁc param-
eters (β5, β7, β13), referred to as “invasive follow-up test
information speciﬁcation stool,” “invasive follow-up test infor-
mation speciﬁcation blood,” and “invasive follow-up test infor-
mation speciﬁcation combi,” to investigate the possible different
effects of this variable among the screening tests. Because of
the labeled design, we included three alternative speciﬁc con-
stants (β0, β6, β8) in the model to reﬂect the three different
labels (stool test, blood test, and combi test). These constants
indicate the attitude of individuals toward a particular screen-
ing test relative to the option not to participate in screening.
The attributes sensitivity, unnecessary follow-up test, and RR
are mean-centered, and the parameters of these variables
for the stool and blood tests are represented by β1, β2, and β3.
We used alternative speciﬁc parameters for the attributes of the
combi test (β9, β10, β11) because this test has different levels in the
DCE than do the stool and blood tests. The attribute level of
evidence is effects coded (i.e., strong evidence ¼ 1, limited
evidence ¼ 1) to avoid confounding with the constant terms,
and it is represented by β4 for the stool and blood tests and β12 for
the combi test.
We analyzed the discrete choice data using a mixed logit
model (in Nlogit 5.0) to take into account the data’s panel
structure as well as the potential heterogeneity in respondents’
preferences. The β’s for the attributes are estimated as ran-
dom coefﬁcients with β þ νi, where νi are IID normally distri-
buted. Thousand Halton draws were used in the estimation
procedure.Results
Respondents
Of the 1277 invited individuals, 721 completed the survey (56.5%).
From these completed survey versions, we were able to use the
data from 631 respondents. More speciﬁcally, 11 respondents were
excluded because they did not fall in the intended age category (i.e.,
55–75 years), 13 respondents were excluded because they have (or
have had) CRC, and 72 respondents were excluded because they
completed the survey in an amount of time that indicated that they
Table 4 – Choice task example for the invasive follow-up test speciﬁcation version*.
Example Stool test Blood test Combi test No
participation
Chance that the screening test correctly identiﬁes
that there is a polyp or CRC Correct for: Correct for: Correct for: –
90 out of 100
people with a
polyp or CRC
70 out of 100
people with a
polyp or CRC
75 out of 100
people with a
polyp or CRC
If there is a polyp or CRC, the screening test
correctly identiﬁes this for… out of 100 people
with a polyp or CRC
Chance of an unnecessary follow-up test Unnecessary
follow-up test
for:
Unnecessary
follow-up test
for:
Unnecessary
follow-up test
for:
–
The screening test incorrectly identiﬁes that
there is a polyp or CRC and thus leads to an
unnecessary follow-up test for
6 out of 100
people without a
polyp or CRC
6 out of 100 people
without a polyp or
CRC
5 out of 100
people without a
polyp or CRC
Risk reduction of CRC death†
Chance decreases
by:
Chance decreases
by:
Chance decreases
by:
–By taking part in screening, the chance that you
die from CRC decreases by … % (from … %
to … %) 50% (from 3.00%
to 1.50%)
30% (from 3.00%
to 2.10%)
45% (from 3.00%
to 1.65%)
Scientiﬁc level of evidence
Based on: Based on: Based on: –
The screening test characteristics “Chance that
the screening test correctly identiﬁes that
there is a polyp or colorectal cancer,” “Chance
of an unnecessary follow-up test,” and “Risk
reduction of CRC death” are based on
A large number of
scientiﬁc studies
(strong evidence)
A small number of
scientiﬁc studies
(limited evidence)
A large number of
scientiﬁc studies
(strong evidence)
Follow-up test‡
The follow-up test (when necessary) to decide
whether there really is a polyp or CRC is a
Colonoscopy Colonoscopy Colonoscopy –
I prefer: Ο
Stool test
Ο
Blood test
Ο
Combi test
Ο
No screening
test
participation
CRC, colorectal cancer.
* The choice task is translated from Dutch.
† Risk reduction levels are based on participation in a screening campaign (i.e., risk reduction resulting from a screening test plus possible
follow-up test).
‡ The follow-up test attribute was included only in the invasive follow-up test speciﬁcation version.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 7 8 – 5 8 7 583had not responded seriously to the task (o4 minutes). This
completion time limit was discussed with and conﬁrmed by
the survey sample provider. Finally, the data of 631 Dutch respond-
ents in the age category 55 to 75 years who have no experience with
CRC were used in the analysis. This ﬁnal dataset contains 310
completes for the version with detailed follow-up test information
and 321 completes that did not receive the additional information.
In total, 303 respondents were men (48%) and 328 were women
(52%), and an almost equal number of responses were available in
the analysis for the different survey versions (101, 104, 105, 103, 104,
and 114 completes, respectively). More demographic details for the
two follow-up test speciﬁcation versions are summarized in
Table 5.
DCE Results
The estimation results (Table 6, model 1) allow us to address our
key research question about the effect of presenting detailed
follow-up test information. We ﬁnd that there are signiﬁcant
negative signs for the parameters estimated for the follow-up test
speciﬁcation variables (i.e., “invasive follow-up test information
speciﬁcation stool,” “invasive follow-up test information speciﬁ-
cation blood,” “invasive follow-up test information speciﬁcationcombi”). In line with our expectations, this indicates that the
chance of choosing a particular screening test decreases when
detailed follow-up test (i.e., colonoscopy) information is provided.
Interestingly, the larger negative sign for the invasive follow-up
test information speciﬁcation parameter for the combi test
indicates that the negative effect is signiﬁcantly larger for the
combi test than for the stool and blood tests. This is conﬁrmed by
WALD tests that show that the null hypothesis of equal param-
eter values is rejected (P o 0.001).
The results also show that the alternative speciﬁc constants
for the blood and combi tests (blood and combi) are signiﬁcant
and have positive signs, indicating that, on average, there is a
greater probability that an individual prefers these tests relative
to no screening. The negative and signiﬁcant alternative speciﬁc
constant for the stool test (stool) suggests that this test is less
attractive than no screening. Furthermore, we ﬁnd signiﬁcant
positive effects on screening test choice for the attributes sensi-
tivity, RR, and level of evidence and a negative effect for the
unnecessary follow-up test attribute for all three screening tests.
This is in line with expectations and indicates that besides the
labels assigned to the three screening tests, their attributes and
levels are of importance. We found no signiﬁcant two-way
interactions between the screening test attributes. Furthermore,
Table 5 – Demographics for the invasive follow-up test information speciﬁcation and the no information
speciﬁcation condition.
Demographic characteristic Invasive follow-up test information
speciﬁcation
No information
speciﬁcation
All
data
How healthy do you normally feel?
(0 ¼ worst health state, 10 ¼ best health state)
7.26 (mean) 7.02 (mean) 7.14
(mean)
Have you ever had a screening test?, n (%)
Yes 61 (19.68) 45 (14.02) 106
(16.80)
No 249 (80.32) 276 (85.98) 525
(83.20)
Have you ever undergone a colonoscopy?, n (%)
Yes 81 (26.13) 75 (23.36) 156
(24.72)
No 229 (73.87) 246 (76.64) 475
(75.28)
Do you know someone who has (had) colorectal
cancer?, n (%)
Yes, from my family or friends/acquaintances 173 (55.80) 187 (58.25) 360
(57.05)
No 137 (44.19) 134 (41.74) 271
(42.95)
What is your sex?, n (%)
Male 142 (45.81) 161 (50.16) 303
(48.02)
Female 168 (54.19) 160 (49.84) 328
(51.98)
What is your age? 62.56 y 63.24 y 62.90 y
What is your ethnicity?, n (%)
I was born in The Netherlands 294 (94.84) 299 (93.15) 593
(93.98)
I was not born in The Netherlands 15 (4.84) 21 (6.54) 36 (5.71)
Don’t know 1 (0.32) 1 (0.31) 2 (0.32)
What is the highest education level you have
achieved?*, n (%)
oHigh school 195 (62.90) 207 (64.49) 402
(63.71)
ZHigh School 114 (36.77) 112 (34.89) 226
(35.82)
Unknown 1 (0.32) 2 (0.62) 3 (0.48)
* Categories are combined.
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and level of evidence for the stool and blood tests, and sensitivity
and level of evidence for the combi test, indicate that individuals
have heterogeneous preferences for these attributes.
To test whether the effect of presenting invasive follow-up test
information also inﬂuences screening test choice via the screening
test attributes, we estimated a second mixed logit model in which
we also included two-way interactions of the invasive follow-up
test information speciﬁcation variables with the attributes (Table 6,
model 2). We found that these interactions were not signiﬁcant,
indicating that presenting detailed follow-up test information does
inﬂuence preferences for particular screening tests but it does not
affect the importance of the screening test attributes.
Predicted Uptake Simulation in the DCE Context
To demonstrate how presenting detailed follow-up test infor-
mation would affect choice shares and predicted uptake, we
used Nlogit 5.0’s simulation procedure. Based on the sample
data, we found the initial choice shares of 14.48%, 28.08,
43.65%, and 13.79% for the stool test, the blood test, the combitest, and the opt-out option, respectively. If we would com-
pare the case in which every individual would be presented
invasive follow-up test information relative to the case in
which every individual would not be presented this informa-
tion, these choice shares would be 15.02%, 28.97%, 39.78%,
16.22% and 13.96%, 27.22%, 47.39%, and 11.43%, respectively.
Thus, the opt-out rate would be 4.79% higher if individuals
were extensively informed about the invasive follow-up test
and its procedure. We also simulated choice shares for a
worst-case screening test and a best-case screening test in
which we assigned the lowest and highest utility attribute
levels for each attribute, respectively.
The resulting choice shares and the choice share differences for
providing versus not providing invasive follow-up test information
are presented in Table 7. They indicate that the decrease in uptake
because of the presentation of invasive follow-up test information
can be explainedmainly by a decrease in choice shares of the combi
test. Furthermore, they show that the decrease in participation
because of the presentation of detailed follow-up test information
would vary between 2.72% (best-case screening test scenario) and
8.14% (worst-case screening test scenario).
Table 7 – Choice shares (%) for invasive follow-up
test information speciﬁcation versus no-informa-
tion speciﬁcation.
Worst Base Best
Invasive follow-up test
information (%)
Stool 10.91 15.02 15.05
Blood 22.91 28.97 31.60
Combi 34.91 39.78 44.94
Opt-out 31.28 16.22 8.41
No information (%)
Stool 10.59 13.96 13.57
Table 6 – Mixed logit model results.
Variables Model 1 Model 2
Coefﬁcients Heterogeneity
components
Coefﬁcients Heterogeneity
components
b SE v SE b SE v SE
Stool (β0) .13* .05 .13* .05
Blood (β6) .61
* .04 .61* .04
Combi (β8) 1.15
* .04 1.15* .04
Sensitivity stool/blood (β1) .02
* .00 .02* .00 .02* .00 .02* .00
Unnecessary follow-up test stool/blood (β2) .07* .01 .00 .02 .07* .01 .00 .02
Risk reduction (RR) stool/blood (β3) .04
* .00 .04* .01 .04* .00 .04* .01
Level of evidence stool/blood (β4) .16
* .02 .16† .07 .16* .02 .16† .07
Sensitivity combi (β9) .02
* .00 .02* .00 .02* .00 .02* .00
Unnecessary follow-up test combi (β10) .03† .02 .00 .02 .03† .02 .00 .02
RR combi (β11) .02
* .00 .00 .01 .02* .00 .00 .01
Level of evidence combi (β12) .15
* .03 .21* .06 .15* .03 .21* .06
Follow-up test info speciﬁcation stool (β5) .14* .05 .14* .05
Follow-up test info speciﬁcation blood (β7) .14* .04 .14* .04
Follow-up test info speciﬁcation combi (β13) .28* .04 .28* .04
Follow-up test info speciﬁcation  Sensitivity stool/blood .00 .00
Follow-up test info speciﬁcation  Unnecessary follow-
up test stool/blood
.01 .01
Follow-up test info speciﬁcation  RR stool/blood .00 .00
Follow-up test info speciﬁcation  Level of evidence
stool/blood
.02 .02
Follow-up test info speciﬁcation  Sensitivity combi .00 .00
Follow-up test info speciﬁcation  Unnecessary follow-
up test combi
.01 .02
Follow-up test info speciﬁcation  RR combi .00 .00
Follow-up test info speciﬁcation  Level of evidence
combi
.02 .03
LL 8962.41 8960.87
DF 22 30
2LL ratio test χ2(8) ¼ 3.08
AIC 2.373 2.375
AIC, Akaike's Information Criterion; DF, degrees of freedom; LL, Log-likelihood; SE, standard error.
* Signiﬁcant at P o 0.01.
† Signiﬁcant at P o 0.05.
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Conclusions
When individuals are extensively informed about the invasive
follow-up test (colonoscopy) in CRC screening, predicted uptake
based on our DCE would be lower compared with the situation in
which such information is not presented. Furthermore, individ-
uals’ noninvasive screening test preferences are affected by
presenting them such follow-up test information. Mixed logit
model analysis and related choice share simulations indicate
that the predicted decrease in uptake because of the presentation
of follow-up test information can be explained mainly by a
decrease in choice shares of the combi test (i.e., the effect is
strongest for the combi test relative to the stool and blood tests).Blood 22.42 27.22 28.72
Combi 43.85 47.39 52.01
Opt-out 23.14 11.43 5.69
Choice share changes (%)
Stool 0.32 1.06 1.48
Blood 0.49 1.75 2.88
Combi 8.94 7.61 7.07
Opt-out 8.14 4.79 2.72Limitations and Further Research
In this section, we present several limitations of our research and
possible considerations that may be interesting for future
research.
A ﬁrst limitation is that we used a large contrast for describing
the follow-up test speciﬁcation versions. The speciﬁc results (i.e.,
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the two speciﬁcation versions) may change when the contrast
between the two versions is less explicitly present. It may there-
fore be interesting for future research to test whether the results
would change when one survey uses the invasive follow-up test
information speciﬁcation version of our study and another uses a
different version that mentions colonoscopy as a follow-up test
attribute, but does not present detailed colonoscopy information,
or a version in which this information is described differently
(e.g., in less detail or in a separate online brochure).
Second, we used a ﬁxed follow-up test as the attribute level
for the invasive follow-up test information speciﬁcation version
(i.e., colonoscopy) and did not include an alternative follow-up
test (level) in the experimental design. The reason for doing this
is that the colonoscopy is regarded as the golden screening
standard and therefore the most realistic follow-up test to be
used in practice [34]. It may, however, be possible that a less
invasive follow-up test such as a ﬂexible sigmoidoscopy is
preferred by a certain group of individuals and that, therefore,
such a test is used. An experimental design that includes the
attribute levels ﬂexible sigmoidoscopy, or other follow-up test
alternatives, such as a colon capsule endoscopy, computed
tomography scan, or other imaging-based procedures, would also
have been interesting to use [35–37]. For example, Howard et al.
[38] investigated preferences for computed tomography colonog-
raphy as an alternative diagnostic test for colonoscopy using a
sample of patients with indications suspicious of CRC.
A third limitation of the study is that the decision task
presented to respondents is different from current screening
practice in The Netherlands. In the present Dutch CRC screening
campaign, individuals are offered a choice between one standard
screening test (i.e., iFOBT) and the option not to participate
in screening, whereas in our DCE, individuals were presented
a choice between three noninvasive screening tests and a
nonparticipation option. Thus, we cannot analyze the case in
which individuals are offered a choice only between one non-
invasive screening test and the option not to participate in
screening. The differences in uptake percentages found between
providing and not providing follow-up test (i.e., colonoscopy)
information to individuals may therefore be different in practice
where individuals face the choice only between one screening
test and the opt-out. Therefore, decision makers should be
cautious when they use the market share changes resulting from
our analysis. It would be interesting for future research to
investigate whether uptake would change when individuals are
offered the choice between one of the three screening tests
presented in this article relative to the case in which they have
a choice only between one screening test and the option not to
take part in screening. An eventual comparison of the results
from such a study with the results of our study would be highly
informative.
Finally, we conclude by noting that DCEs reveal stated
preferences and that individuals’ actual participation decision
(or screening test choice) may be different when invasive follow-
up test information is provided (or not) in a real life setting
because the stated preference and revealed preference data may
differ [39,40].
Theoretical and Managerial Implications
As far as we know, this is the ﬁrst DCE-based study that
speciﬁcally focuses on the typical nature of screening campaigns
in which individuals are invited to do a screening test ﬁrst, and,
second, in case of a positive screening test result are advised to
undergo a more invasive follow-up test. Although there are many
studies that measure individuals’ preferences for screening tests
in the literature, we are unaware of a study that separates theeffect of information about an eventual invasive follow-up test
from the effect of noninvasive screening test information in
individuals’ decision to participate in screening. In earlier
research, there were also studies that implicitly addressed the
issue of follow-up testing by including attributes such as the
number of false-positives or unnecessary colonoscopies [1–
5,9,10,13,14], but in these studies it was not investigated how
the presentation of detailed information about invasive follow-up
testing would affect screening test choice and uptake in a CRC
screening campaign context in which individuals are ﬁrst invited
to participate in noninvasive screening. This distinction is highly
relevant because it optimally reﬂects the current Dutch screening
campaign practice in which individuals are invited to perform a
noninvasive screening test before more invasive follow-up test-
ing in test-positive cases.
With this article, we build on the existing literature that
focuses on measuring individuals’ preferences for CRC screening
tests by demonstrating how providing detailed information about
a possible future follow-up test (i.e., colonoscopy) affects individ-
uals’ screening participation and screening test decision. This also
relates to recent research that showed that the consideration of
future consequences plays a role in screening participation deci-
sions [15]. In this context, our article speciﬁcally adds that detailed
follow-up test information should also be considered because we
found that it affects screening participation. The present study
also has implications for the design of future DCEs because it
highlights that it is crucial to provide important contextual
information in screening participation decisions. Note that when
a person with a positive noninvasive screening test result decides
not to participate in follow-up testing (undergoing a colonoscopy),
this may lead to not only undesired consequences such as worries
for the person in question but also inefﬁciency of campaign-based
CRC screening in general. Providing all necessary follow-up test
information at once would therefore be better.
The results of this study pose new challenges for decision
makers in practice who aim not only to increase uptake but also
to provide full disclosure to screening participants given the
moral need to accurately inform the public regarding screening
and its consequences. Policymakers may use our ﬁndings, for
instance, for the development of screening invitations. Although
they could present follow-up test information in a separate
brochure or on a screening-related Web site to put less direct
attention on the invasiveness of the follow-up test, we advocate
that given the principle of informed choice—which is well
respected in The Netherlands—it is not an option to omit
relevant follow-up test information. Decision makers should
therefore ﬁnd other ways to compensate for the predicted
reduction in uptake caused by the presentation of information
about the follow-up test. This could be done, for example, by
emphasizing a screening test’s high expected reduction in mor-
tality risk or by providing information about a screening test’s
level of scientiﬁc evidence. For example, by mentioning the fact
that the screening test’s characteristics (i.e., its sensitivity,
speciﬁcity, and RR levels) are supported by a large number of
scientiﬁc studies (i.e., strong scientiﬁc evidence), the negative
effect caused by the presentation of invasive follow-up test
information could be compensated.Acknowledgments
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